A heptacyanine-type ferroptosis inducer and its synthesis and application
By developing Qijiachuan Cyclone ferrody death inducers to target tumor mitochondrial depletion of glutathione, the problem of difficulty in achieving accurate and non-invasive tumor treatment in the prior art has been solved, and effective inhibition and detection of tumors has been achieved. Excellent anti-tumor effect.
Patent Information
- Application Number
- CN202310259534.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-03-17
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2043-03-17
AI Technical Summary
Existing tumor treatment methods are difficult to achieve accurate diagnosis and non-invasive treatment, and cannot effectively inhibit tumor recurrence, especially because the junction between normal tissue and tumor cannot be accurately judged, and routine treatment causes great harm to the patient's body.
A ferrodysmortality inducer of Qijiachuan Cyclone was developed. This small molecule induces ferrody death by targeting tumor mitochondria to deplete glutathione, thereby achieving tumor treatment. This small molecule exhibits ultraviolet and fluorescence differences by responding specifically to biothiols such as cysteine, homocysteine and glutathione, and can target tumor cells, deplete glutathione and reduce GPX4 expression. , increase lipid peroxide and induce ferrous death.
This small molecule shows a specific killing effect on tumor cells, can significantly inhibit tumor growth, and has the potential for selective in vitro detection and in vivo treatment, showing excellent anti-tumor effects, and the synthesis method is simple and easy to implement.
Smart Images

Figure BDA0004130683120000021 
Figure BDA0004130683120000022 
Figure BDA0004130683120000031
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medicinal chemistry, and specifically relates to a heptamethine cyanine-type ferroptosis inducer and its synthesis and application. Background Art
[0002] Cancer is a serious threat to human life and health, causing tens of thousands of deaths every year. It is the most threatening disease to human life and health. At present, surgical resection, chemotherapy or radiotherapy are mainly used to treat malignant tumors in clinical practice. However, single treatment methods, such as surgical resection and radiotherapy, are often difficult to produce ideal tumor treatment effects. At the same time, due to the inability to accurately judge the boundary between normal tissue and tumor-invaded lesion tissue, conventional treatment methods usually cause great harm to the patient's body and are difficult to cure the tumor and inhibit tumor recurrence. Therefore, accurate treatment and non-invasive treatment methods for tumor diagnosis and imaging are still huge challenges for today's medicine.
[0003] Ferroptosis is a new type of programmed cell death that is different from apoptosis, necrosis, and autophagy. It is mainly caused by the increase of intracellular divalent iron ion content, which causes lipid peroxidation and inactivation of glutathione peroxidase 4 (GPX4) through the Fenton reaction. It has received increasing attention from researchers in recent years. When cells undergo ferroptosis, the main manifestations are the decrease of intracellular redox-related GPX4 expression level and the increase of lipid peroxide level, accompanied by the increase of cell mitochondrial membrane density and changes in mitochondrial morphology. Glutathione (GSH) is the most critical small molecule biological thiol synthesized from glutamate, cysteine, and glycine. It is synthesized only in the cytoplasm and transported to the mitochondria under the regulation of the mitochondrial membrane carrier SLC25A39. GSH in mitochondria mainly binds to GPX4 to participate in the redox cycle, and plays a role in scavenging reactive oxygen species (ROS) that have a killing effect on cells. When the GSH content in the mitochondria decreases, the activity of GPX4 is inhibited and the expression level is reduced. The intracellular ROS, especially lipid peroxides, cannot be cleared in time, which will induce cell ferroptosis. However, there are currently no reports on small molecule drugs that can target tumor mitochondria to deplete glutathione and induce ferroptosis. Summary of the invention
[0004] The purpose of the present invention is to provide a heptamethine cyanine-based ferroptosis inducer and its synthesis and application. The heptamethine cyanine-based ferroptosis inducer is a heptamethine cyanine derivative, which can target tumor mitochondria to deplete glutathione and induce ferroptosis, thereby achieving the effect of treating tumors.
[0005] To achieve the purpose of the present invention, the following embodiments are provided.
[0006] In one embodiment, a heptamethine cyanine derivative of the present invention has a compound represented by formula I,
[0007]
[0008] I
[0009] Wherein, n=3-6;
[0010] X is O, S or Se,
[0011] R1 is hydrogen or alkyl,
[0012] R2 is hydrogen, halogen or alkyl, provided that when X is O, R2 is not hydrogen and alkyl.
[0013] Y - They are iodide ion, chloride ion and bromide ion.
[0014] Preferably, the heptamethine cyanine derivatives of the present invention are
[0015] In formula I, n=3; X is O, S or Se, R1 is hydrogen, R2 is F, Cl, Br, methyl, ethyl, propyl or butyl, preferably F, Y - It is iodide ion.
[0016] In another embodiment, the present invention provides a method for preparing a heptamethine cyanine derivative, wherein the heptamethine cyanine derivative is a compound represented by formula I,
[0017] The reaction formula is as follows:
[0018]
[0019]
[0020] comprising reacting a compound of formula C with The reaction gives a compound of formula ID, or
[0021] The compound of formula C is reacted with the compound of formula E to obtain the compound of formula IF,
[0022] Among them, R1, R2, Y - The definition of is the same as above, and X is O or S.
[0023] In another embodiment of the above, the method for preparing the heptamethine cyanine derivative is carried out in a reaction solvent containing a basic additive, wherein the basic additive is triethylamine or NaH, or the reaction solvent is N,N-dimethylformamide or anhydrous ether.
[0024] In another embodiment of the above, the method for preparing the heptamethine cyanine derivative further comprises the preparation of the compound of formula E,
[0025]
[0026] The method comprises reacting an aryl magnesium bromide Grignard reagent of formula G with selenium in an organic solvent ether under nitrogen protection, and then adding hydrochloric acid for treatment to obtain an aryl selenol of formula E.
[0027] In another embodiment of the above, the preparation method of the heptamethine cyanine derivative, the compound C, is prepared by the following method, comprising the following steps:
[0028]
[0029] 1) Cyclohexanone reacts with phosphorus oxychloride (POCl3) in DMF to obtain compound A;
[0030] 2) 2,3,3-trimethyl-3H indole derivatives react with halogenated alkane in acetonitrile to obtain indole quaternary ammonium salt B;
[0031] 3) Compound A prepared in step 1) and indole quaternary ammonium salt B prepared in step 2) are added to ethanol to obtain compound C under nitrogen protection.
[0032] In a specific embodiment, a method for preparing a heptamethine cyanine derivative is provided, wherein the heptamethine cyanine derivative is a compound represented by formula I, and the reaction formula is as follows:
[0033]
[0034] In the formula, n=3; X is O, S or Se, R1 is hydrogen, R2 is F, Y - For iodide ions, comprising the following steps:
[0035] 1) N,N-dimethylformamide (DMF) is used as the reaction solvent, phosphorus oxychloride (POCl3) and cyclohexanone are slowly added dropwise in an ice bath, and then the temperature is slowly raised to 45°C for 6 hours. After the reaction is completed, the reaction solution is precipitated with ice water, filtered, and the filter cake is recrystallized with ethyl acetate to obtain condensation agent A;
[0036] 2) Acetonitrile (MeCN) is used as the reaction solvent, and the 2,3,3-trimethyl-3H indole derivative and the halogenated alkane are heated to reflux at 110°C for 16 hours under nitrogen protection. After the reaction is completed, the residue is concentrated by rotary evaporation, and the residue is washed with ethyl acetate to obtain indole quaternary ammonium salt B;
[0037] 3) using anhydrous ethanol as a reaction solvent and sodium acetate as an alkaline additive, reacting the condensing agent A obtained in step 1) with the indole quaternary ammonium salt B obtained in step 2) at 70° C. for 3 h under nitrogen protection, concentrating the reaction solution under reduced pressure to obtain a residue, and separating the residue by column chromatography to obtain an indole cyanine dye intermediate C;
[0038] 4) using N,N-dimethylformamide as a reaction solvent and sodium hydride (NaH) or triethylamine (TEA) as an alkaline additive, reacting the phenol derivative or thiophenol derivative with the indole cyanine dye intermediate C obtained in step 3) at room temperature overnight under nitrogen protection, concentrating the reaction solution under reduced pressure to obtain a residue, and separating by column chromatography to obtain cyanine dye D (also called ID compound);
[0039] 5) Anhydrous ether (Et2O) is used as the reaction solvent, and the aryl magnesium bromide Grignard reagent is slowly added dropwise to the selenium ether reaction solution. After reacting at room temperature for 30 minutes under nitrogen protection, a 3 mol / L hydrochloric acid (HCL) solution is added and stirred for 5 minutes to quench the reaction. The reactant is extracted with anhydrous ether, separated, the organic phase is collected and dried with anhydrous sodium sulfate, filtered, and the filtrate is concentrated under reduced pressure to obtain aryl selenol E, which is directly used for the next step reaction; anhydrous ether is used as the reaction solvent, and triethylamine is used as the alkaline additive. The aryl selenol E obtained in step 5) and the indole cyanine dye intermediate C obtained in step 3) are reacted at room temperature for 24 hours under nitrogen protection, and the reaction solution is concentrated under reduced pressure to obtain a residue, which is separated by column chromatography to obtain cyanine dye F (also known as IF compound).
[0040] Preferably, in the preparation method of the present invention, the molar ratio of cyclohexanone:POCl3:DMF in step 1) is 3:1:2, the molar ratio of indocyanine dye intermediate C:phenol derivative or thiophenol derivative:alkaline additive (sodium hydride or triethylamine) in step 4) is 1:2:2-1:10:2, and the molar ratio of indocyanine dye intermediate C:aryl selenol E:triethylamine in step 6) is 1:2:2-1:10:2.
[0041] Preferably, in the preparation method of the present invention, the eluent for column chromatography in step 3), step 4) and step 6) is a mixed solvent of dichloromethane and methanol, and the volume ratio of dichloromethane:methanol is 60:1-90:1.
[0042] The present invention also provides the use of the compound shown in formula I as a multifunctional ferroptotic cyanine small molecule inducer in the preparation of a tumor imaging agent. Preferably, the imaging agent is used for tumor mitochondrial accumulation, fluorescence and photoacoustic dual-modality imaging.
[0043] The compound represented by formula I of the present invention is used as a multifunctional ferroptotic cyanine small molecule inducer in ultraviolet and fluorescence selective response to biological thiols such as cysteine (Cys), homocysteine (Hcy) and glutathione (GSH). Preferably, the drug exhibits specific ultraviolet and fluorescence responsiveness to glutathione and exhibits an "OFF-ON" effect.
[0044] The present invention also provides the use of the compound shown in formula I in the preparation of anti-tumor drugs. The compound shown in formula I induces ferroptosis by targeting tumor mitochondria to deplete glutathione, thereby achieving an anti-tumor effect.
[0045] Specifically, the compound represented by formula I of the present invention is used as a multifunctional ferroptosis cyanine small molecule inducer in targeting tumor mitochondria to deplete glutathione and thereby induce ferroptosis anti-tumor effect.
[0046] The compound represented by formula I of the present invention is composed of a heptamethine indole cyanine conjugated chain with tumor targeting capability and an aromatic group with electron regulation capability bridged by an oxygen element. Based on the difference in molecular electronic effects, it can show differential ultraviolet and fluorescence responsiveness to different biological thiols (cysteine, homocysteine and glutathione), and exhibit an "OFF-ON" effect.
[0047] The compound inducer represented by formula I of the present invention can target tumor cell mitochondria, deplete glutathione and thereby induce ferroptosis anti-tumor effect, and exhibits a good inhibitory effect on the growth of solid tumors.
[0048] The synthesis reaction conditions of the compound represented by formula I of the present invention are mild, the synthesis method is simple and easy to operate, and the compound has good transformation and application prospects for being developed into a ferroptotic cyanine small molecule inducer for selective in vitro ultraviolet and fluorescence detection of various biothiols and in vivo tumor treatment.
[0049] The inventors have discovered that a heptamethine indole cyanine skeleton modified with three or more carbon alkyl side chains can be selectively and efficiently accumulated in the mitochondria of tumor cells. The aromatic groups with different electronic properties are bridged with the cyanine skeleton targeted to tumor mitochondria through oxygen elements (oxygen, sulfur, and selenium). Based on computer-aided and density functional calculations (DFT), a multifunctional ferroptosis cyanine small molecule inducer is rationally designed and synthesized, which can selectively exhibit ultraviolet and fluorescence differential responsiveness to different biological thiols (cysteine, homocysteine, and glutathione) in vitro and exhibit an "OFF-ON" effect. At the same time, it can also target tumor cell mitochondria, deplete glutathione, and thereby induce ferroptosis anti-tumor effects, and exhibit good tumor cell killing effects.
[0050] Studies have shown that the compounds shown in formula I of the present invention, under the electron-withdrawing induction effect of the aromatic group on the cyanine skeleton, the electron density of the fluorophore cyanine skeleton that can be used for excitation is reduced, and it is manifested as extremely weak fluorescence emission in aqueous solution. Under the nucleophilic attack of different biological thiols (cysteine, homocysteine and glutathione), the aromatic structure part of the coupled cyanine skeleton leaves, forming a new biological thiol-cyanine skeleton complex, and showing a differential fluorescence response, wherein the specific ultraviolet and fluorescence "OFF-ON" effect is shown for glutathione (GSH). In addition, the compounds of formula I of the present invention can also accumulate in tumor cell mitochondria, specifically respond to GSH and deplete it, thereby reducing the expression level of GPX4, increasing the level of lipid peroxides, inducing ferroptosis, and exerting a tumor cell killing effect.
[0051] The compound represented by formula I of the present invention is a small molecule inducer of ferroptotic cyanine, which has the ability of targeted accumulation in solid tumors, near-infrared fluorescence and photoacoustic dual-modality imaging, and can significantly inhibit the growth of solid tumors after targeted accumulation in tumor sites, showing a good anti-tumor effect, and can be used as a small molecule drug for the precise treatment of tumors. BRIEF DESCRIPTION OF THE DRAWINGS
[0052] Figure 1 This is the UV spectrum of the compound obtained by in vitro detection of biological thiol responsiveness in Example 8;
[0053] Figure 2 This is a fluorescence spectrum of the compound obtained by in vitro detection in Example 8 in response to biological thiol;
[0054] Figure 3 This is the anti-interference fluorescence spectrum of compound IR780-SPhF in Example 9;
[0055] Figure 4 The antitumor activity of the compound IR780-SPhF and its derivatives in Example 10;
[0056] Figure 5 The compound IR780-SPhF in Example 11 preferentially aggregates in tumor cells rather than normal cells;
[0057] Figure 6 This is the mitochondrial colocalization map of compound IR780-SPhF in Example 12;
[0058] Figure 7 The compound IR780-SPhF in Example 13 depletes intracellular and mitochondrial GSH;
[0059] Figure 8 This is a WB graph of the GPX4 expression level mediated by the compound IR780-SPhF of Example 14;
[0060] Fig. 9 This is a fluorescence graph of lipid peroxide levels mediated by compound IR780-SPhF of Example 15;
[0061] Fig.10 This is a diagram showing the changes in mitochondrial morphology mediated by the compound IR780-SPhF of Example 16;
[0062] Fig.11 This is the tumor-targeted near-infrared fluorescence in vivo imaging image of the compound IR780-SPhF of Example 17;
[0063] Fig.12 This is the tumor-targeted photoacoustic imaging image of the compound IR780-SPhF of Example 17;
[0064] Fig.13 This is a comparison chart of tumor volume, weight change and size after 14 days of treatment with compound IR780-SPhF in Example 18. DETAILED DESCRIPTION
[0065] The present invention is described in detail below through preferred embodiments so that the essence and advantages of the present invention can be more easily understood by those skilled in the art. Any equivalent replacement or change made by those skilled in the art based on the technical solution and inventive concept of the present invention shall fall within the protection scope of the present invention.
[0066] Reagents and instruments used in the examples:
[0067] The chemical reagents and solvents used were purchased from Sigma-Aldrich, Adamas, Greagent or Aladdin Reagent Company. The solvents acetonitrile, ethanol and N,N-dimethylformamide (DMF) were purchased ultra-dry solvents and used directly.
[0068] The synthesis of cyanine small molecules was carried out under nitrogen and light-proof conditions, and the reaction progress was visually monitored using a silica gel thin layer chromatography plate (model GF-254) produced by Rushan Sun Desiccant Co., Ltd. The remaining reactions were visually monitored after irradiation with a 254nm ultraviolet lamp.
[0069] The distillation grade organic reagent produced by Greagent Reagent Company was used for column chromatography separation and purification of cyanine molecules. The silica gel (200-300 mesh) used for column chromatography was produced by Yantai Zhifu Huangwu Silica Gel Development and Experimental Factory.
[0070] The H NMR spectra of all compounds ( 1 H-NMR) was measured by a 600 MHz nuclear magnetic resonance spectrometer produced by Agilent Corporation of the United States, using CDCl3 as solvent, and the unit of δ value is ppm.
[0071] The high-resolution mass spectrometry (HRMS) of all compounds was performed by QTOF6550 and Orbitrp Exploris produced by Agilent, USA. TM The UV absorption spectrum was measured by UV-3600 UV-visible fluorescence spectrophotometer produced by SHIMADZU Co., Ltd. of Japan; and the fluorescence spectrum was measured by F380 fluorescence spectrometer produced by Gangdong Technology Co., Ltd. of China.
[0072] The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples are all commercially available unless otherwise specified.
[0073] Example 1 Synthesis of Compound A
[0074]
[0075] Add 50 mL of N,N-dimethylformamide (DMF) to a 250 mL round-bottom flask, slowly drop 34 mL of phosphorus oxychloride (POCl3) and cyclohexanone (10 g, 0.1 mol) in turn under an ice bath, and then slowly raise the temperature to 45 ° C for 6 hours. After the reaction is completed, the reaction solution is precipitated with ice water, filtered, and the filter cake is recrystallized with ethyl acetate to obtain the condensation agent compound A, which is directly used in the next step reaction.
[0076] Example 2 Synthesis of Compound B
[0077]
[0078] 2,3,3-Trimethyl-3H-indole (10 mmol, 1.59 g) and iodopropane (10 mmol, 1.70 g) were added to a 100 mL round-bottom flask, and 20 mL of acetonitrile (MeCN) was used as the reaction solvent. The mixture was heated to reflux at 110 °C for 16 h under nitrogen protection. After the reaction was completed, the residue was concentrated by rotary evaporation, and the residue was washed with ethyl acetate and recrystallized to obtain propane indole quaternary ammonium salt B.
[0079] Example 3 Synthesis of Indocyanine Dye Intermediate C
[0080]
[0081] In a 50 mL round-bottom flask, propane indole quaternary ammonium salt B (4.28 mmol, 1.41 g) and condensation agent A (2.14 mmol, 0.37 g) were added, 10 mL of anhydrous ethanol was used as the reaction solvent, sodium acetate (5.89 mmol, 0.48 g) was used as the alkaline additive, and the mixture was reacted at 70 ° C for 3 h under nitrogen protection. The reaction solution was concentrated under reduced pressure to obtain a residue, which was separated by column chromatography to obtain indole cyanine dye intermediate C.
[0082] Example 4 Synthesis of ferroptotic cyanine small molecule inducer IR780-OPhF
[0083]
[0084] 4-Fluorophenol (109 mg, 0.9 mmol) and sodium hydride (NaH, 21.6 mg, 0.9 mmol) were added to a 25 mL round-bottom flask, and 2 mL of N,N-dimethylformamide (DMF) was used as the reaction solvent. After 15 min of reaction at room temperature under nitrogen protection, indole cyanine dye intermediate C (100 mg, 0.15 mmol) was added to the above reaction solution, and the reaction was continued at room temperature under nitrogen protection for 24 h. After the reaction was completed, the reaction solution was concentrated under reduced pressure to obtain a residue, which was separated by column chromatography (dichloromethane / methanol = 90 / 1, v / v) to obtain ferroptotic cyanine small molecule inducer IR780-OPhF (78.6 mg, 71% yield). 1 H-NMR (600MHz, CDCl3) δ7.85(d,J=13.8Hz,2H),7.36–7.34(m,2H),7.26–7.04(m,10H),6.09(d,J=13.8Hz ,2H),4.08(s,4H),2.74(s,4H),2.05(s,2H),1.87(s,4H),1.35(s,12H),1.06–1.04(m,6H)ppm.HRMS[MI] + Calculate for C 42 H 48 FN2O + ,615.3745;found,615.3745.
[0085] Example 5 Synthesis of ferroptotic cyanine small molecule inducer IR780-SPhF
[0086]
[0087] In a 25mL round-bottom flask, indole cyanine dye intermediate C (100mg, 0.15mmol), 4-fluorothiophenol (190.7mg, 1.5mmol) and triethylamine (TEA, 50μL) were added, and 2mL N,N-dimethylformamide (DMF) was used as the reaction solvent. The reaction was carried out at room temperature for 12h under nitrogen protection. After the reaction was completed, the reaction solution was concentrated under reduced pressure to obtain a residue, which was separated by column chromatography (dichloromethane / methanol = 60 / 1, v / v) to obtain the ferroptotic cyanine small molecule inducer IR780-SPhF (87.8mg, 77% yield). 1H-NMR (600MHz, CDCl3) δ8.65 (d, J = 14.4Hz, 2H), 7.36 (t, J = 7.8Hz, 2H), 7.30 (d ,J=7.8Hz,2H),7.22–7.17(m,4H),7.13(d,J=8.4Hz,2H),6.98(t,J=8.4Hz,2H) ,6.25(d,J=13.8Hz,2H),4.14(t,J=7.2Hz,4H),2.79(t,J=6.0Hz,4H),2.06–2. 02(m,2H),192–1.86(m,4H),1.50(s,12H),1.05(t,J=7.2Hz,6H)ppm.HRMS[MI] + Calculate for C 42 H 48 FN2S + ,631.3517;found,631.3518.
[0088] Example 6 Synthesis of Aryl Selenol E
[0089]
[0090] Selenium (236.9 mg, 3 mmol) and 5 mL of anhydrous ether (Et2O) were added to a 25 mL round-bottom flask as the reaction solvent. 4-Fluorophenylmagnesium bromide (3.75 mL, 0.8 M in THF) was slowly added dropwise under nitrogen protection and reacted at room temperature for 30 min. After the reaction was completed, 4 mL of 3 mol / L hydrochloric acid (HCL) solution was added and stirred for 5 min to quench the reaction. The reactants were extracted with 20 mL of anhydrous ether, separated, the organic phase was collected and dried with anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain aryl selenol E, which was directly used in the next step.
[0091] Example 7 Synthesis of ferroptotic cyanine small molecule inducer IR780-SePhF
[0092]
[0093] Indole cyanine dye intermediate C (100 mg, 0.15 mmol) and aryl selenol E (190.7 mg, 1.5 mmol) were added to a 25 mL round-bottom flask, and 10 mL of anhydrous ether (Et2O) was used as the reaction solvent. The reaction was carried out at room temperature under nitrogen protection for 24 h. After the reaction was completed, the reaction solution was concentrated under reduced pressure to obtain a residue, which was separated by column chromatography (dichloromethane / methanol = 70 / 1, v / v) to obtain the ferroptotic cyanine small molecule inducer IR780-SePhF (86 mg, 71% yield). 1H-NMR (600MHz, CDCl3) δ8.72 (d, J = 14.4Hz, 2H), 7.37–7.34 (m, 2H), 7.33–7.30 (m, 2H), 7. 28–7.27(m,1H),7.21(t,J=7.2Hz,2H),7.12(d,J=8.4Hz,2H),7.01(t,J=9.0Hz,1H),6.9 6(t,J=9.0Hz,2H),6.24(d,J=14.4Hz,2H),4.13(t,J=7.2Hz,4H),2.79(t,J=6.0Hz,4H), 2.05–2.00(m,2H),1.92–1.86(m,4H),1.52(s,12H),1.05(t,J=7.8Hz,6H)ppm.HRMS[MI] + Calculate for C 42 H 48 FWf + ,679.2961;found,679.2961.
[0094] Example 8 UV and fluorescence spectroscopy in vitro detection of responsiveness to biothiols
[0095] Weigh 10 mg of compound IR780-OPhF, IR780-SPhF and IR780-SePhF accurately with an analytical balance, and prepare them into 10 mM stock solution with dimethyl sulfoxide (DMSO) for later use. Weigh 10 mg of cysteine (Cys), homocysteine (Hcy) and glutathione (GSH) accurately with an analytical balance, and prepare them into 10 mM stock solution with ultrapure water for later use. Take an appropriate amount of IR780-SPhF 10 mM stock solution and dissolve it in 3 centrifuge tubes containing 3 mL of phosphate buffer (PBS, 10 mM, PH = 7.4) to make the final concentration 6 μM. Use UV3600 UV spectrophotometer and Lumina Fluorescence Spectrometer fluorescence spectrometer to measure the UV absorption and fluorescence emission spectra of the solution. Then, appropriate amounts of Cys, Hcy and GSH were added to the above three centrifuge tubes to make a final concentration of 3 mM, and the ultraviolet and fluorescence spectra were immediately measured after shaking and incubating in a 37°C shaker for 0 s, 20 s, 40 s, 1 min, 2 min, 3 min, 5 min, 10 min, 15 min and 20 min. The ultraviolet and fluorescence responsiveness of compounds IR780-OPhF and IR780-SePhF to Cys, Hcy and GSH were measured in the same way. Figure 1 and 2As shown, among these three cyanine small molecule compounds, compound IR780-SPhF exhibits specific UV and fluorescence selective responsiveness to Cys, Hcy and GSH, and exhibits an "OFF-ON" effect.
[0096] Example 9 Anti-interference fluorescence experiment of compound IR780-SPhF
[0097] 10 mg of cysteine (Cys), homocysteine (Hcy), glutathione (GSH), glutamine (Gln), lysine (Lys), arginine (Arg), glycine (Gly), alanine (Ala), serine (Ser), valine (Val), glutamic acid (Glu), aspartic acid (Asp), methionine (Met), proline (Pro), phenylalanine (Phe), tyrosine (Try), isoleucine (Ile), leucine (Leu), tryptophan (Trp), aspartic acid (Asn), histidine (His), and threonine (Thr) were accurately weighed using an analytical balance, and prepared into a 10 mM stock solution with ultrapure water for later use. An appropriate amount of IR780-SPhF 10 mM stock solution was taken and dissolved in 23 centrifuge tubes containing 3 mL of phosphate buffer (PBS, 10 mM, pH = 7.4) to make a final concentration of 6 μM. Then, appropriate amounts of Cys, Hcy, GSH, Gln, Lys, Arg, Gly, Ala, Ser, Val, Glu, Asp, Met, Pro, Phe, Try, Ile, Leu, Trp, Asn, His, and Thr were added to the above 22 centrifuge tubes to make a final concentration of 3 mM. The remaining centrifuge tube was used as a control group. After shaking and incubating in a shaker at 37°C for 10 min, the fluorescence emission spectra of the solutions were measured using a fluorescence spectrometer. Figure 3 As shown, various amino acids did not significantly interfere with the response of IR780-SPhF to GSH.
[0098] Example 10 Antitumor activity of compound IR780-SPhF and its derivatives
[0099] 4T1 cells were seeded in a 96-well plate and cultured in an incubator for 24 hours. Then, 0 μM, 0.1 μM, 0.2 μM, 0.4 μM, 0.8 μM, and 1.6 μM IR780-OPhF, IR780-SPhF, and IR780-SePhF were added and incubated for 24 hours. Then, 10 μl of CCK-8 reagent was added to each well and incubated for 2-4 hours. The absorbance at 450 nm was recorded. The cell survival rate was calculated as follows: Figure 4 As shown in Figure 2, compounds IR780-OPhF, IR780-SPhF, and IR780-SPhF have good antitumor activity. Among them, IR780-SPhF has the most significant antitumor activity, with an IC50 At the same time, 0μM, 2μM, 4μM, 8μM, 15μM, and 25μM IR780 were selected as controls, and their antitumor activities were evaluated under the same conditions, and their IC 50 7.6μM. Figure 4 The results showed that the anti-tumor activity of IR780-OPhF, IR780-SPhF, and IR780-SPhF was significantly better than that of IR780.
[0100] Example 11 IR780-SPhF preferentially accumulates in tumor cells rather than normal cells
[0101] 4T1 cells and MFC-10A cells were inoculated in confocal microplates and cultured in an incubator for 24 hours. Then, 0.2 μM IR780-SPhF was added and incubated for 1 hour, and images were taken under a confocal microscope. Figure 5 As shown, IR780-SPhF aggregated more obviously in tumor cells 4T1 than in normal cells MFC-10A.
[0102] Example 12 Compound IR780-SPhF mitochondrial targeting experiment
[0103] 4T1 cells were inoculated in a confocal dish and cultured in an incubator for 24 hours. Then, 0.2 μM IR780-SPhF was added and incubated for 4 hours. The commercial mitochondrial probe Mito-Tracker was then added and incubated for 30 minutes before imaging under a laser confocal microscope. Figure 6 As shown, the fluorescence of IR780-SPhF and the mitochondrial probe Mito-Tracker are almost completely overlapped, indicating that IR780-SPhF has excellent mitochondrial targeting.
[0104] Example 13 IR780-SPhF depletes GSH in cells and mitochondria
[0105] 4T1 cells were inoculated in a 6-well plate and cultured in an incubator for 24 hours. IR780-SPhF (0 μM, 0.4 μM, 0.8 μM, 1.6 μM) was added and incubated for 12 hours. The GSH levels in cells and mitochondria (mitochondria were isolated using a mitochondrial isolation kit) were measured using a glutathione kit. Figure 7 As shown, IR780-SPhF depleted GSH in cells and mitochondria, and the depletion ratio of GSH in mitochondria was more obvious than that in cells.
[0106] Example 14 Experiment on GPX4 expression level mediated by compound IR780-SPhF
[0107] 4T1 cells were inoculated in a 6-well plate and cultured in an incubator for 24 hours. After the cells were treated with ferroptosis inhibitors Liproxstatin-1 and IR780-SPhF (grouped into: control group, 0.4μM IR780-SPhF group, 0.8μM IR780-SPhF group, Liproxstatin-1+0.8μM IR780-SPhF group), the cells were collected, proteins were extracted, and the level of GPX4 was detected by Western Blot. The extracted proteins were separated by sodium dodecyl sulfate-polyacrylamide gel and then transferred to a PVDF membrane. The membrane was blocked with 5% BSA and then incubated with the primary antibody GPX4 overnight at 4°C. Subsequently, the membrane was incubated with a secondary antibody labeled with horseradish peroxidase. Finally, the ECL reagent was used for detection. Figure 8 As shown, IR780-SPhF can reduce the level of GPX4, and the ferroptosis inhibitor Liproxstatin-1 can upregulate the level of GPX4.
[0108] Example 15 Experiment on lipid peroxide levels mediated by compound IR780-SPhF in tumor cells
[0109] 4T1 cells were seeded in 6-well plates and cultured in an incubator for 24 hours. After treatment with ferroptosis inhibitors Liproxstatin-1 and IR780-SPhF (grouped into: control group, 0.8 μM IR780-SPhF group, Liproxstatin-1 group, Liproxstatin-1 + 0.8 μM IR780-SPhF group), the cells were treated with lipid peroxide probes for 30 minutes, and imaged under a fluorescence microscope. Fig. 9 As shown, IR780-SPhF can increase the content of lipid peroxides, and the ferroptosis inhibitor Liproxstatin-1 can reduce the level of lipid peroxides.
[0110] Example 16 Mitochondrial Morphological Changes
[0111] 4T1 cells were inoculated in a 6-well plate and cultured in an incubator for 24 hours. IR780-SPhF (0, 0.6 μM) was added and incubated for 24 hours. The mitochondrial morphology was observed under an electron microscope. Fig.10 As shown in Figure 2, mitochondrial morphology changed after IR780-SPhF treatment, with mitochondria becoming smaller, mitochondrial membrane density increasing, and mitochondrial cristae decreasing or disappearing.
[0112] Example 17 Tumor targeting ability of compound IR780-SPhF
[0113] 100 μL, 0.25 mg / kg IR780-SPhF was injected into the tail vein of 4T1 tumor-bearing mice, and near-infrared fluorescence imaging and photoacoustic imaging were performed at 0.5 h, 1 h, 6 h, 24 h, 48 h, and 72 h, respectively. Fig.11 (Near-infrared fluorescence imaging) and Fig.12 (Photoacoustic imaging) shows that IR780-SPhF can quickly accumulate in the tumor site and is cleared quickly, with little accumulation in various organs.
[0114] Example 18 Evaluation of the in vivo antitumor effect of compound IR780-SPhF
[0115] The tumor-bearing mice were randomly divided into 4 groups (n=5 / group), control group, IR780-SPhF 2.5mg / kg group, IR780-SPhF 5mg / kg group and cyclophosphamide (CTX20mg / kg) group. IR780-SPhF 2.5mg / kg, IR780-SPhF 5mg / kg and CTX20mg / kg were intraperitoneally injected every 2 days, and repeated 4 times. In the control group, all animals were given the same volume of PBS each time. The changes in tumor volume were recorded every 3 days, and the mice were sacrificed after 14 days of treatment. Fig.13 As shown, the volume and weight of tumors in mice treated with IR780-SPhF were smaller than those in the control group, showing an effective anti-tumor effect in a dose-dependent manner, and the tumor inhibition effect was superior to that of the clinically positive drug CTX group.
Claims
1. A heptamethine cyanine derivative having a compound shown in formula I, Wherein, n=3-6; X is O, S or Se, R1 is hydrogen, R2 is halogen, Y - They are iodide ion, chloride ion and bromide ion.
2. The heptamethine cyanine derivative according to claim 1, wherein in formula I, n=3, X is O, S or Se, R1 is hydrogen, R2 is F, Y - It is iodide ion.
3. The heptamethine cyanine derivative according to claim 1 or 2, selected from the following compounds:
4. A method for preparing the compound of formula I according to claim 1, The reaction formula is as follows:
5. The preparation method according to claim 4, wherein the reaction is carried out in a reaction solvent containing an alkaline additive.
6. The preparation method according to claim 5, wherein the alkaline additive is triethylamine or NaH, or the reaction solvent for preparing ID is N,N-dimethylformamide.
7. The method of claim 4, comprising the preparation of a compound of formula E, The method comprises reacting an aryl magnesium bromide Grignard reagent of formula G with selenium in an organic solvent ether under nitrogen protection, and then adding hydrochloric acid for treatment to obtain an aryl selenol of formula E.
8. The method according to claim 4, wherein the compound C is prepared by the following method, comprising the following steps: 1) Cyclohexanone reacts with phosphorus oxychloride (POCl3) in DMF to obtain compound A; 2) 2,3,3-trimethyl-3H-indole reacts with halogenated alkane in acetonitrile to obtain indole quaternary ammonium salt B; 3) Compound A prepared in step 1) and indole quaternary ammonium salt B prepared in step 2) are added to ethanol to obtain compound C under nitrogen protection.
9. Use of the compound of formula I according to claim 1 or 2 or the IR780-OPhF, IR780-SPhF and IR780-SePhF compounds according to claim 3 in the preparation of anti-4TI tumor drugs.
